Table 1.
Demographic and Clinical Characteristics of Individuals Initiating and Receiving Antiretroviral Therapy in El Salvador, 2018–2019a
| Characteristic | ART Initiators (n = 260) | PHIV Receiving ART for 12 ± 3 mo (n = 230) | PHIV Receiving ART for ≥48 mo (n = 425) | |||
|---|---|---|---|---|---|---|
| No. | % (95% CI) | No. | % (95% CI) | No. | % (95% CI) | |
| Gender | ||||||
| Female | 54 | 23.9 (17.3–32.2) | 62 | 22.6 (17.8–28.2) | 211 | 47.1 (42.2–52.0) |
| Male | 200 | 72.5 (64.0–79.7) | 164 | 75.6 (69.7–80.6) | 213 | 52.6 (47.6–57.4) |
| Transgender | 6 | 3.5 (1.4–8.7) | 4 | 1.8 (.6–5.5) | 1 | 0.4 (.1–2.3) |
| Age, y | ||||||
| ≤25 | 57 | 22.3 (15.9–30.3) | 42 | 19.0 (11.3–30.2) | 13 | 4.2 (2.4–7.3) |
| >25 | 203 | 77.7 (69.7–84.1) | 188 | 81.0 (69.8–88.7) | 412 | 95.8 (92.7–97.6) |
| Current ART line | ||||||
| First-line | 260 | 100.0 (98.5–100.0) | 229 | 99.7 (98.6–99.9) | 337 | 83.4 (80.4–86.0) |
| Second-line | NA | … | 1 | 0.3 (.1–1.4) | 87 | 16.5 (13.8–19.5) |
| Third-line | NA | … | 0 | 0.0 (0–1.6) | 1 | 0.2 (.0–.6) |
| Current ART regimen | ||||||
| TDF + 3TC/FTC + EFV | 235 | 91.7 (87.6–94.5) | 216 | 93.5 (89.1–96.2) | 113 | 23.8 (20.1–27.9) |
| TDF + 3TC/FTC + NVP | 2 | 1.6 (.3–8.8) | 1 | 0.2 (.2–.2) | 10 | 2.3 (1.3–3.9) |
| ZDV + 3TC/FTC + EFV | 9 | 2.9 (1.7–4.8) | 7 | 4.5 (2.1–9.1) | 167 | 44.9 (40.2–49.7) |
| ZDV + 3TC/FTC + NVP | 2 | 0.6 (.2–1.5) | 0 | 0.0 (.0–1.6) | 30 | 8.5 (6.0–11.8) |
| PI-based | 3 | 0.7 (.4–1.2) | 1 | 0.3 (.1–1.4) | 93 | 17.7 (15.0–20.7) |
| Other | 9 | 2.5 (1.6–3.9) | 5 | 1.5 (.8–3.0) | 12 | 2.9 (1.6–5.2) |
Abbreviations: 3TC/FTC, lamivudine/emtricitabine; ART, antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NA, not applicable; NVP, nevirapine; PI, protease inhibitor; PHIV, people with human immunodeficiency virus; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.
a
Study design–weighted proportions and 95% CIs.